SunWay Biotech Co., Ltd. Statistics
SunWay Biotech Co., Ltd. (1271) Stock Statistics & Valuation Metrics
Total Valuation
SunWay Biotech Co., Ltd. has a market cap or net worth of TWD 4.31B. The enterprise value is ―.
- Market Cap
- TWD 4.31B
- Enterprise Value
- ―
Share Statistics
SunWay Biotech Co., Ltd. has 77,089,066 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 77,089,066
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
SunWay Biotech Co., Ltd.’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 2.16%.
- Return on Equity (ROE)
- 0.03
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 2.16%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 17.13M
- Profits Per Employee
- 1.75M
- Employee Count
- 58
- Asset Turnover
- 0.22
- Inventory Turnover
- 2.28
Valuation Ratios
The current PE Ratio of SunWay Biotech Co., Ltd. is 25.84. SunWay Biotech Co., Ltd.’s PEG ratio is 0.57.
- PE Ratio
- 25.84
- PS Ratio
- 2.22
- PB Ratio
- 0.87
- Price to FCF
- 61.00
- Price to Operating Cash Flow
- 16.60
- PEG Ratio
- 0.57
Income Statement
In the last 12 months, SunWay Biotech Co., Ltd. had revenue of 993.30M and earned 101.49M in profits. Earnings per share was 1.68.
- Revenue
- 993.30M
- Gross Profit
- 560.50M
- Operating Income
- 104.13M
- Pretax Income
- 115.42M
- Net Income
- 101.49M
- EBITDA
- 197.44M
- Earnings Per Share (EPS)
- 1.68
Cash Flow
In the last 12 months, operating cash flow was 218.06M and capital expenditures -162.30M, giving a free cash flow of 55.76M billion.
- Operating Cash Flow
- 218.06M
- Free Cash Flow
- 55.76M
- Free Cash Flow per Share
- 0.87
Dividends & Yields
SunWay Biotech Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 1.40%
- Dividend Per Share
- ―
- Dividend Yield
- 1.40%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.66%
- Earnings Yield
- 3.82%
Stock Price Statistics
- Beta
- -0.02
- 52-Week Price Change
- -13.73%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 33.23
- Average Volume (3m)
- 46.00K
Financial Position
SunWay Biotech Co., Ltd. as a current ratio of 1.62, with Debt / Equity ratio of 27.18%
- Current Ratio
- 1.62
- Quick Ratio
- 1.23
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- 2.97
- Interest Coverage Ratio
- 9.25
Taxes
In the past 12 months, SunWay Biotech Co., Ltd. has paid 13.93M in taxes.
- Income Tax
- 13.93M
- Effective Tax Rate
- 0.12
Enterprise Valuation
SunWay Biotech Co., Ltd. EV to EBITDA ratio is 24.41, with an EV/FCF ratio of 76.90.
- EV to Sales
- 2.79
- EV to EBITDA
- 24.41
- EV to Free Cash Flow
- 76.90
- EV to Operating Cash Flow
- 19.66
Balance Sheet
SunWay Biotech Co., Ltd. has TWD 726.41M in cash and marketable securities with TWD 1.65B in debt, giving a net cash position of -TWD 922.60M billion.
- Cash & Marketable Securities
- TWD 726.41M
- Total Debt
- TWD 1.65B
- Net Cash
- -TWD 922.60M
- Net Cash Per Share
- -TWD 11.97
- Tangible Book Value Per Share
- TWD 13.25
Margins
Gross margin is 46.87%, with operating margin of 6.27%, and net profit margin of 8.90%.
- Gross Margin
- 46.87%
- Operating Margin
- 6.27%
- Pretax Margin
- 9.88%
- Net Profit Margin
- 8.90%
- EBITDA Margin
- 11.44%
- EBIT Margin
- 6.27%
Analyst Forecast
The average price target for SunWay Biotech Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 61.34%
- EPS Growth Forecast
- 45.14%
